EF Hutton Assumes Sonnet BioTherapeutics at Buy, Announces Price Target of $6.7
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Michael King assumes Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and announces a price target of $6.7.
May 25, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics receives a Buy rating from EF Hutton analyst Michael King, with a price target of $6.7.
The Buy rating and price target announcement by EF Hutton analyst Michael King is likely to have a positive short-term impact on Sonnet BioTherapeutics' stock price. Investors may see this as a sign of confidence in the company's potential, leading to increased demand for the stock and a potential price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100